Detail akcie Futura Medical online

Business Summary: Futura Medical plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development and sale of pharmaceutical and healthcare products. It is focused on developing a portfolio of products based on its transdermal DermaSys technology. The DermaSys is designed to deliver clinically proven medical treatments via the skin. DermaSys platform with penetration and permeation enhancer components tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action. Such targeted delivery offers an optimized profile in terms of dose, onset time and duration of effect. The Company's products include MED3000 and TPR100. The Company's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The Company has conducted a Phase III study using MED3000 in ED. The Company is also developing CBD100, which is a topical cannabidiol formulation.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Futura Medical PLC revenues increased from L3.1M to L13.9M. Net income totaled L1.3M vs. loss of L6.5M. Revenues reflect EU and UK segment increase of 75% to L4.8M, Rest of the world (Region) segment increase from L375K to L1.3M. Net Income reflects Development and commercialisation segment income totaling L1.2M vs. loss of L7M.